In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor
with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS),
smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL).